4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
(NASDAQ:FDMT), 4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336 million in potential regulatory and commercial milestones and tiered double-digit royalties depending on net sales in Otsuka's territories Proceeds […]